Akari Therapeutics (FRA:CLA) DeferredTaxAndRevenue : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Akari Therapeutics's current deferred tax and revenue for the quarter that ended in Mar. 2024 was €0.00 Mil.

Akari Therapeutics DeferredTaxAndRevenue Historical Data

The historical data trend for Akari Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics DeferredTaxAndRevenue Chart

Akari Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

DeferredTaxAndRevenue

Get a 7-Day Free Trial

Akari Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Dec23	Mar24
DeferredTaxAndRevenue	Get a 7-Day Free Trial															-	-	-	-	-

Akari Therapeutics DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Akari Therapeutics (FRA:CLA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

AKTX:USA

Address

75/76 Wimpole Street, London, GBR, W1G 9RT

Website

https://www.akaritx.com

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing inhibitors of acute and chronic inflammation which includes the complement system, the bioamine system and the eicosanoid system for the treatment of rare and orphan diseases. Its main product candidate includes Coversin, Coversin long acting and Coversin dual action. It operates mainly in United States and United Kingdom.